Global diagnostic company, Anbio Biotechnology (NNNN) priced its initial public offering of 1.6M shares at $5.00 per share.

The Company expects to receive aggregate gross proceeds of US$8 million from the Offering, before deducting underwriting discounts and other related expenses. The Offering is expected to close on or ...

The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...

Anbio Biotechnology NNNN IPO will take place February, 19 on the NASDAQ exchange under the ticker NNNN. The company is offering shares at an expected price between $5.00 and $6.00 per share with an ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

The most notable insider purchases of the past week came from return buyers, including Warren Buffett. A biotech IPO also ...

An earlier version of this story misspelled the name of Smithfield Foods Inc. in its headline. Smithfield Foods Inc. is offering Wall Street a seat at the table for potential growth in its ...

The heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for ...

Cornerstone Research recently issued its 2024 Year in Review report examining recent trends in securities class action filings. For the second year ...

This content was published on Feb 14, 2025 Swiss National Bank defends negative interest rates as an important tool for taming the Swiss franc. This content was published on Feb 7, 2025 The ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Various biotech companies have completed or launched their IPOs so far in 2025. As of early February, five sizeable life sciences companies ...